alpha-MSH analog comes up often in conversation and rarely with the context attached. Here we lay out the basics in order, then work through the practical considerations.
Updated 2026-05-09. Numbers and descriptions here follow the published literature rather than marketing material.
Research interest has centred on photoprotection and pigmentation, with a smaller body of work on appetite and sexual function. Published human data remain limited to small, frequently uncontrolled studies, and the compound has never received marketing approval from a national medicines regulator. Most laboratory work treats it as a pharmacological tool for probing melanocortin signalling in cell culture or animal models. Whether pigmentation changes observed in people translate into measurable protection against ultraviolet-induced DNA damage remains an open question.
Melanotan-2 is a synthetic cyclic heptapeptide designed as an analogue of alpha-melanocyte-stimulating hormone, the naturally occurring peptide involved in pigmentation signalling. Its sequence is conventionally written as Ac-Nle-cyclo[Asp-His-D-Phe-Arg-Trp-Lys]-NH2, with a lactam bridge joining the aspartate side chain to the lysine side chain. The empirical formula is C50H69N15O9 and the monoisotopic mass lies near 1023.5 daltons. N-terminal acetylation and the D-configured phenylalanine both increase resistance to enzymatic breakdown compared with the parent hormone.
Early published reports described melanotan-2 as a tanning agent without sun protection, which means darkening is not the same as protection against ultraviolet radiation. Later studies explored the peptide in erectile dysfunction, hemorrhagic shock, and some skin conditions. No regulator in the United States or Europe has approved it for clinical use. Many products labelled melanotan-2 are sold without approval and their identity and purity are unverified. Its long-term safety in humans remains an open question.
Melanotan-2, also written Melanotan II, is a synthetic cyclic heptapeptide designed as an analogue of alpha-melanocyte-stimulating hormone. Its sequence is Ac-Nle-cyclo[Asp-His-D-Phe-Arg-Trp-Lys]-NH2, and the lactam bridge between the aspartate and lysine side chains constrains the peptide into a ring. This structural change increases receptor affinity and metabolic stability relative to the native hormone. The compound was created in the 1980s as a research tool for studying pigmentation biology.
| Property | Value | Notes |
|---|---|---|
| Common synonyms | Melanotan II; MT-II; N-acetyl-norleucyl-cyclo[Asp-His-D-Phe-Arg-Trp-Lys] amide | Naming follows peptide convention; the numeral distinguishes it from melanotan-1 |
| Molecular formula | C50H69N15O9 | Includes the lactam bridge; no counter-ion assumed |
| Monoisotopic mass | 1023.53 Da | Free base; salts and counter-ions shift the observed value |
| Appearance | White to off-white lyophilised powder | Batch-to-batch colour variation is not itself proof of impurity |
| Typical analytical method | RP-HPLC purity determination with ESI-MS identity confirmation | Retention time alone does not establish sequence identity |
Receptor studies place melanotan-2 among non-selective melanocortin agonists, binding MC1R, MC3R, MC4R and MC5R rather than a single subtype. Activation of MC1R on cutaneous melanocytes raises tyrosinase activity and shifts pigment synthesis toward eumelanin, which is darker and more photostable than pheomelanin. Central receptors, particularly MC4R, are associated with appetite suppression and with reported effects on sexual function. Because subtype selectivity is low, the same molecule engages pigment, metabolic and vascular pathways at once, and this breadth is a common explanation offered for the range of adverse events described in user reports.
No regulatory authority has approved melanotan-2 for human use, and several countries classify it as a prescription-only or controlled substance, which restricts lawful supply. Material sold online is generally labelled as a research chemical and is not required to meet pharmaceutical standards of identity or purity. Published human data consist mainly of small uncontrolled studies, case reports and adverse-event notifications, so the evidence base is descriptive rather than confirmatory. Whether repeated melanocyte stimulation alters long-term naevus behaviour remains an open question that no completed trial has resolved.
Melanotan-2 is a synthetic cyclic heptapeptide designed as a structural analogue of alpha-melanocyte-stimulating hormone, the endogenous tridecapeptide that regulates pigment production. Two modifications distinguish it from the natural hormone: norleucine replaces methionine at the N-terminus, which limits oxidation, and a D-phenylalanine substitution raises receptor affinity. The ring is closed through an aspartate-lysine lactam bridge, giving the molecule a constrained conformation. The free base has a molecular mass near 1024 daltons, and commercial material is usually supplied as an acetate salt. It appears in the literature as a research peptide rather than an approved therapeutic agent.
Published pharmacokinetic information is limited and comes mainly from small studies rather than registrational trials. Plasma half-life is usually described as short, on the order of tens of minutes, followed by rapid tissue distribution and clearance of the intact peptide. Metabolites and low concentrations of parent compound have been reported in urine, a detail relevant to anti-doping and forensic testing. Whether repeated exposure changes receptor sensitivity or clearance over time remains an open question. Values differ noticeably between analytical assays, so published numbers should be read as approximate rather than definitive.
Melanotan II is a synthetic cyclic heptapeptide with the sequence Ac-Nle-cyclo[Asp-His-D-Phe-Arg-Trp-Lys]-NH2, corresponding to a molecular formula of C50H69N15O9 and a monoisotopic mass near 1024 daltons. It was designed as a structural analogue of alpha-melanocyte-stimulating hormone, a peptide hormone produced by cleavage of proopiomelanocortin. A lactam bridge between the aspartate and lysine side chains closes the ring, and the C-terminal amide removes a free carboxyl group. Both modifications increase resistance to enzymatic degradation compared with the linear parent hormone. Four substitutions distinguish it from afamelanotide, the linear analogue studied under the name melanotan I.
The compound emerged from research programs in the 1980s that examined analogues of alpha-melanocyte-stimulating hormone for pigmentation and photoprotection. Investigators modified the native sequence to extend activity duration and potency. A related analogue, afamelanotide, was developed within the same broad line of inquiry and eventually gained approval in certain jurisdictions for a rare light-sensitivity condition. Melanotan-2 itself did not progress through the same regulatory route and has no approved therapeutic indication.
Melanocortin receptors comprise five subtypes with distinct tissue distributions and functions. Melanotan-2 is described in the literature as a non-selective agonist that engages several of these subtypes, including MC1R, MC3R, MC4R, and MC5R. MC1R is the subtype most directly linked to melanin production in skin cells. Because the compound is not subtype-selective, its observed effects in experimental settings are generally attributed to activity across multiple receptor pathways rather than to a single target.
Outside regulated medicine, melanotan II circulates through online vendors as a research chemical, often marketed for tanning. Products sold this way vary widely in purity, concentration, and labeling accuracy, and independent testing has documented discrepancies. Published reports describe both pigment effects and adverse reactions, including nausea, flushing, and darkening of existing moles. Long-term safety data are sparse, and no large controlled trial has established a risk profile. Questions about cumulative effects on melanocytes remain unresolved in the literature.
Melanotan II is a synthetic peptide analog modeled on alpha-melanocyte-stimulating hormone, a naturally occurring signaling peptide involved in pigmentation. Its structure is a cyclic heptapeptide containing two non-natural substitutions, norleucine at position four and D-phenylalanine at position seven. These modifications resist enzymatic breakdown and extend the molecule's activity relative to the native hormone. The compound binds melanocortin receptors and is studied mainly as a pharmacological tool rather than a therapeutic product. It has never received approval as a medicine in any major jurisdiction.
=== Saline injection === Injection in saline is normally conducted intramuscularly (IM) in skeletal muscle, or intradermally (ID), delivering DNA to extracellular spaces. This can be assisted either 1) by electroporation; 2) by temporarily damaging muscle fibres with myotoxins such as bupivacaine; or 3) by using hypertonic solutions of saline or sucrose. Immune responses to this method can be affected by factors including needle type, needle alignment, speed of injection, volume of injection, muscle type, and age, sex and physiological condition of the recipient.
compared perianal injectable bulking agents to sphincter training and biofeedback, and found the former to be superior. Both methods lead to an improvement of FI, but comparisons of St Mark's scores between the groups showed no difference between treatments. Anal manometry is sometimes used to investigate changes in the anal canal before and after the procedure. Usually mean anal resting pressure and mean anal squeeze pressure are the parameters used. Improvements in these measurements are often, but not always reported up to 3–12 months after the procedure. These improvements are not always maintained after 12 months. The length of the anal canal has also been reported to increase following the procedure. In one report, dextranomer did not increase anal resting or squeeze pressures. In the same study, dextranomer injections were found to be no different to biofeedback. There is limited research available on this topic, and these publications are mostly of poor quality. Apart from the available research, most of the claims of benefit of these procedures is anecdotal. One author criticized these procedures, stating that simply narrowing the anal canal was an instinctive and naïve solution which does not consider the complex pathopysiological mechanisms of FI. They suggested that these treatments are in theory suitable only for passive and minor forms of FI. Concerns have been raised about migration of the particles (in the case of Durasphere) away from the site of injection, or the total resorption of the material (in the case of hyaluronic acid and hydroxyl coaptite).
=== Veterinary use === An SSRI (fluoxetine) has been approved for veterinary use in treatment of canine separation anxiety. Like in human medicine, fluoxetine is extensively used off-label in animal medicine. In dogs and cats, it is mainly prescribed off-label for behavior problems.
=== Australia === Fuel prices at the petrol and diesel stations started soaring in early March in Australia, partly driven by panic buying. More critical to overall inflationary forces though, is the supply of diesel to drive heavy machinery. Australia's diesel is largely dependent on refineries in Singapore, South Korea, Malaysia, Taiwan and India. Experts have warned that the increased price of diesel would lead to much higher food prices, threatening both food security and the "just-in-time" logistics infrastructure that serves food retailers.Australia holds around 29 to 36 days' reserves of fuel, and a large proportion of this was released to support retailers in regional areas. If the Strait of Hormuz continues to be blocked, the Liquid Fuel Emergency Act 1984 could be triggered, which allows for formal transaction limits and rationing of fuel. This act was passed in response to the 1970s fuel crisis, and has not been triggered since then. In the meantime, the government has lowered the standard for the flash point for both diesel and petrol, which will make it easier for the country's two refineries to produce more fuel. In mid-March, the state governments of Victoria and Tasmania made public transport free to all users, for differing fixed time periods. On 30 March 2026, the Australian Government under Prime Minister Anthony Albanese, after a meeting of National Cabinet, announced a National Fuel Security Plan, to coordinate responses across all states and territories of Australia.
== Diagnosis == It is important to consider a potential cardiovascular cause of hoarseness particularly in patients with progressive disease. Once suspected, performing a laryngoscopy is the first step in identifying damage to the left recurrent laryngeal nerve. Examination includes:
Sources: en.wikipedia.org
=== Development === The project started with producer Mace Neufeld, and was intended as a prestige thriller headlined by James Caan but that version stalled due to difficulties with the script. Neufeld later partnered with Moshe Diamant to pitch it, under the title Heart of Stone, to football player and aspiring actor Brian Bosworth. Diamant's Epic Productions had formed a joint venture with Michael Douglas and Rick Bieber's Stonebridge Entertainment called the Stone Group and the Douglas connection was an added incentive to Bosworth. Joining the other executive producers was Gary Wichard, Bosworth's personal manager who had spearheaded his transition to movies. Producer duties were entrusted to Yoram Ben Ami, CEO of Triumph Releasing, a Columbia Pictures subsidiary that usually dealt with Diamant's product. During pre-production, the screenplay was attributed to Walter Doninger and Howard Cushnir (the latter is absent from the final credits). It was retooled for Bosworth, who consulted with the writers over about one year. A late pre-production report claimed that the story was to be set in the Midwest. However, Ben Ami indicated that the Deep South region had been chosen because it was in the script, and some of the eventual locations had been in talks to host since at least summer 1989.
Teneurin C-terminal associated peptides (TCAPs) are a family of highly conserved 40–41 amino acid peptides encoded within the C-terminus of the type II transmembrane proteins known as teneurins that are involved with cell adhesion. TCAPs are proposed to be liberated by proteolytic cleavage from the parent protein. Once released, TCAPs have been shown in have been shown in HEK293 cell assays and rodent models to act as to act as soluble neuromodulatory and metabolic regulators that influence neuronal morphology, synaptic connectivity, and stress responsiveness, in part via cytoskeletal remodeling, enhanced energy generating oxidative metabolism in some contexts, and based on in vitro studies, functional interaction with adhesion GPCRs of the latrophilin family.
== Haas atomic model == In 1910, Arthur Erich Haas proposed a model of the hydrogen atom with an electron circulating on the surface of a sphere of positive charge. The model resembled Thomson's plum pudding model, but Haas added a radical new twist: he constrained the electron's potential energy,
On the basis of Gennaro's histological studies and the present amino acid and Cu and Fe analyses, I conclude that, to the extent the preserved O. giganteus tissue is representative of the carcass washed ashore at St. Augustine, Florida, in November 1896, it was essentially a huge mass of collagenous protein. Certainly, the tissue was not blubber. I interpret these results as consistent with, and supportive of, Webb and Verrill's identification of the carcass as that of a gigantic cephalopod, probably an octopus, not referable to any known species.
Sources: en.wikipedia.org
It is a synthetic cyclic heptapeptide analogue of alpha-melanocyte-stimulating hormone, containing seven amino acids with a lactam ring and a D-configured phenylalanine residue. It is supplied as a lyophilised powder for laboratory research.
The natural hormone is a linear tridecapeptide that is rapidly degraded in circulation. Melanotan-2 is shortened, cyclised, N-terminally acetylated, and carries a D-amino acid substitution, all of which slow enzymatic breakdown.
No national medicines regulator has approved melanotan-2 for therapeutic or cosmetic use. In several jurisdictions it is treated as an unapproved prescription medicine, and its legal classification differs from country to country.
No. It is a laboratory-made peptide, while the natural hormone is alpha-melanocyte-stimulating hormone, a longer peptide produced by the pituitary gland and by skin cells. Melanotan-2 mimics only a short active region of that hormone and contains non-natural residues such as D-phenylalanine.